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Abstract. FK506 was used in 71 liver transplant 
recipients who. whtleon cyciosponne based immunosup-
pressIOn. were sujferingfrom cbromc or acute reJection. 
When the hiochemical and histopathologIc parametersfor 
response to FK506 conversion were studied. it was evident 
that the subsets of patients with acute and chrome reJec-
tion sustamed a statisticaiiy signljkant Improvement in 
liver function. Those patients with coextstmg hepatztis in-
I '(Jivmg the liveraiiograft. when converted to FK506. had 
some Improvement In biochemIcal parameters. However. 
h istopathologicaiiv. 35 percent of these livers showed pro-
gressIVe involvement with hepatitis. 
Introduction 
Cyclosporine has been a major advance in the arma-
mentarium of immunosuppressive agents used in clinical 
transplantation. The use of cyclosponne and steroids ha ve 
increased patient and graft survival in liver transplanta-
tion.!. 2 Cyclosporine has been shown [Q inhibit inter-
leukin-2 synthesis and therefore inhibit T cell prolifera-
tion. :\evertheless. clinical rejection occurs in over 60 
percent of all liver transplant recipients. Rejection contin-
ues to be a common cause of retransplantatlon. and death 
IS often a sequelae of treatment of rejection. A number of 
adverse effects of cyclosporine have been well defined: 
nephrotoxicity. hypertension. neurotoxicity and hirsut-
ism. Also. a number of less well defined side effects have 
been described. Alterations in clinical immunosuppres-
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sion to prevent or reverse these and other side effects have 
included: 1) reduction of cydosporine dose. or 2) addition 
of azathoprine. antilymphocyte antibodies (ALG) or other 
agents with concomitant reductions in the cyclosponne 
dose. These methodologies have their inherent dangers. 
i.e .. increasing susceptibility to rejection and infection. 
respective Iv. 
FKS06 is a potent and novel immunosuppressIve 
agent. The innial use of FKS06 was for conversion of liver 
transplant patients considered to have failed cyclosponne 
therapy and was termed "rescue therapy'. Our first report 
included 40 patients who received FK506 because they 
were rejecting their liver grafts in spite of conventional 
immunosuppression.3 The initial protocol combined low 
doses of FK506 with cyclosporine. however. this combina-
tion was accompanied by a number of adverse reactions. 
Eventually, it was learned that both drugs compete for 
metabolism via similar pathways so that a clean conver-
sion was subsequently made for patients who were under-
going rescue therapy. 
A larger series of patients. which included 246 pa-
tients. was reported at the XIII International Congress of 
the Transplantation Society. We confirmed the benefIcial 
biochemical response of failing liver allografts under 
cyclosporine therapy to FK506 rescue therapy: Patients 
with acute rejection and to a lesser extent. chronic rejec-
tion. responded well to FK506 conversion. 
The following is a summary of clinicopathologic 
analysis of cyclosporine treated liver transplant reCIpIents 
with either chrontc or acute rejection. These patients were 
converted from cyclosporine. steroids and/or azathi-
oprine to FKS06 with or without low dose steroids. 
Patients and Methods 
Study Design. This trial was conducted at the Univer-
sity of Pittsburgh. Presbyterian University Hospital. 
Childrens Hospital and the Veterans Administration 
Medical Center. with the approval of the respective Insti-
tutional Review Boards. Informed consent was obtained 
from patients or their appointed guardians. The accrual 
period for this study began on February 28 1989 and 
continued to December 311989. A minimum followup 
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period of nine months was obtained on all patients. 
Patient Profiles. Seventy-one patients were selected 
for study during this period of time. Most were bearing 
their first liver allograft at the time of the conversion from 
cyclosponne to FK 506. A smaller number of patients had 
previouslv received more than one previous liver trans-
plant. e.g., one patient was carrying his fifth liver trans-
plant at the time of FK506 conversion. 
The median time from transplantation to FK'506 con-
version was 21 months. range 0.1 to 78 months. The 
median age was 42 years. range 1 to 66 years of age. The 
sex distribution was slightly male predominant. 
Indicatzons. The 71 patients in the study suffered from 
a wide vanety of hepatic disorders requiring transplanta-
tion. .\lost had cryptogenic cirrhosis or post-necrotic 
cirrhosis due to non A-non B hepatitis (27 percent). 
Cholestattc cirrhosIs (27 percent) and alcoholic cirrhosIs 
(18 percent) made up the other large categories. 
. \11 patients SWItched to FK506-based immunosup-
pressIOn were selected for this study based on: 1) bio-
chemical graft dvsfunction defined by elevated liver func-
tion tests (>50 percent) over the lowest value In the prior 
week and unresponsiveness to standard augmented 
immunosuppression; 2) no evidence of mechanical dys-
function: .3) lack of significant concomitant infections; 4) 
adequate pathologic documentation. both prior to and 
after FK506 conversion. Prior to conversion to FK506. 
maintenance immunosuppression in all patients consisted 
of cyclosporine and prednisone. with or without azathi-
oprine. Cyclosporine doses had been maximized to toler-
able levels. as limited by renal dysfunction or hyperten-
sion. Seventy percent of the patients had received at least 
one course of OKT3 prior to conversion to FK506. 
The indications for FK506 conversion are shown in 
Table 1. In several instances. more than one coexistent in-
dication was present. Rejection was the indication for 
treatment in all 71 patients. Acute rejection was seen in 18 
allografts. Chronic rejection was seen in 33 allografts. 
Coexistent hepatitis and chronic rejection was seen in an-
other 20 patients. 
Pathologic evaluations. Biopsies were taken at the 
initiation of FK506 therapy and within two months follow-
ing FK506 conversion. All liver biopsies were reviewed by 
a single pathologist (A]D). Biopsy specimens were fixed 
in neutral buffered formalin and routinely stained with 
hematoxylin and eosin. trichrome and reticulin stams. 
The follOWing histologic criteria were used for the pa-
thologic diagnosiS of acute hepatic rejection: 
1. A portal tract inflammatory infiltrate consisting of 
50-60 percent mononuclear cells intermixed with poly-
morphonuclear cells and eosinophils. 
2. Characteristic localization of the inflammatory cells 
around and beneath the swollen endothelium of portal 
capillaries and small veins with infiltration and damage of 
the epithelium of small bile ductules. The number of 
damaged bile ductules and the degree of damage gener-
allv increased with time. The most severe changes. WIth 
c.luctular loss. were seen in chromc relectlon . 
3. Absence of histologic findings suggesuve of hepa-
titis. 
A diagnosis of chronic hepatic rejection was made if 
there was evidence of: 
l. The obliterative arteriolar lesions that have been 
found in liver as well as other solid organs.!. 5 
2. Loss of intrahepatic bile ducts. often with only a 
mild peri- and intraductal chronic inflammatory infiltrate. 
3. Portal fibrosis. especially if linkage had occurred 
between portal tracts or central veins. 
4. Absence oflobular changes suggesung hepatitis. 
An attempt was made to quantify changes associated 
with "chronic" rejection. A diagnOSIs of "earlv" chronic 
relection was made when there was eVidence of lympho-
cytic bile duct damage in <50 percent of portal triads and 
bile duct loss limited to <25 percent of triads Without 
cholestatic or hepatitic changes. "Late" chronic relection 
was defined by duct loss in >50 percent of portal triads. 
with lymphocytic bile duct damage in remaining triads and 
with hepatocanalicular cholestasis. 
TABLEl. 
INDICATIONS AND STATUS OF FK506 RESCUE A TrEMPTS 
Indication for Rescue ~ FunctionIng # Failed # Died Total 
Acute Rejection 14 3 18 
Chronic Rejection 22 11 0 33 
Chronic Rejection 
with Hepatitis 16 4 0 20 
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A diagnosis of hepatitis was made if there was evi-
denceof: 
1. Significant panlobular mtlammatlon. piecemeal ne-
crosis. cholangiolar proliferation. disarray with ballooning 
;lnd spotty individual hepatocyte necrosis and prominent 
lymphohistiocvtic infiltration of the hepatic lobule with 
int1ammatory cell destruction of hepatocytes. The forego-
ing are not prominent features of rejection under immuno-
suppressIon and suggest a diagnosis of viral hepatitis. 
2. Positive staining for viral protems or positive 
growth of virus from liver biopsy specimens. 
Timing and details of therapy: Cyclosporine was dis-
continued 24 hours prior to initiation of FK506 therapy. 
Initiation of treatment with FKS06 was done in the hospital 
;lnd was gIven initially as a parenteral dose with conver-
sion to ;ln oral dose. The inital parenteral dose of FK506 
was 0.07'5 to 0.1 '5 mg; kg given mtravenously over a period 
of four hours. Generallv, oral dosages ot FK'506 were 
gIven :u U . .30 mg; kg in divided doses. Dose adlustments ot 
FK506 were based upon monnoring at serum trough 
levels bv ELISA" and also bv adjustment according to 
clinical or biochemical parameters. The factor of hepatic 
dysfunction tn reducing mamtenance doses of FK506 has 
been emphasized in recent studies.-
Statistlcal analysis. Liver function tests were evalu-
ated using a two-tailed Student'S t-test. with unequal 
variances. Probability values <0.0'5 were considered sta-
tistically significant. 
Results 
Patient and Graft Suroival: In this population of 71 
patients . .3 deaths occurred (4.2 percent) while 15 grafts 
were lost because of the need for retransplantauon. 
Deaths occurred in patients who required FK506 conver-
~ion. Two deaths were from sepsis while one death was 
in a patient with metastatic hepatoma. When the causes of 
retransplantauon were correlated with the indications for 
entrance into the study, the highest rate of failure was seen 
in those patients with chromc rejection with or without 
coexisting hepatitis. 
BiochemIcal response of the liver allograft. The bio-
chemical response of the liver allografts to FK506 was 
broken down into the specific indications for which the 
patients were switched to FK506. 
A total of 18 patients were analyzed in this group. Four 
patients were removed from analysis. one because of 
retransplantation and 3 because of death. This left 14 
remaining patients with documented acute rejection. The 
mean values for total bilirubin. SGOT and SG PT. prior to 
FK506 were: 8.3 mg;dL. 96 lUlL and 216 lUlL. respec-
tively. These values fell. by the sixth month, to: 0.5 mgldL. 
65 lUlL and 82 lUlL. respectively. Both the alkaline 
phosphatase (ALK) and gamma glutamyl transpeptidase 
(GGTP) also fell (215 IU/L to 164 IU/Land 284 IU/L to 123 
lUlL, respectively). 
Patients with an entrance diagnosis of chronic relec-
tion also had a beneficial response to FK506. Table 2 
shows the response of the 33 patients with chromc 
rejection who were analyzed. Eleven of the .33 grafts 
failed. requiring retransplantation. This left 22 grafts 
available for further analYSis. The pre-FK506 values for 
total bilirubin. SGOT and SGPT for the 11 patients who 
required retransplantation were: 21.0 mgtdL. 282 IU/L and 
-il2 IU/L. respectively. The corresponding values for the 
patients with chronic rejection who kept their grafts were: 
of.3 mgt dL. 204 IU/L and 297 IU/L. While the total bilirubin 
fell to normal values by six months, (1.1 mg/dU. the 
average transaminase values were sull elevated above 
nonnal values at six months (SGOT and SGPT: 97 lUlL and 
126 lUlU. The ALK and GGTP levels tn the responding 
group also fell bv six months (478 IU/Lto .326 lUlL for ALK. 
and 1316 IUlLto 677 IU/LforGGTP). Theliverdysfunc-
tion was Significantly worse in patients with chronic relec-
tion whose grafts failed as compared to those whose grafts 
were successfully rescued. 
In 20 patients in whom hepatitiS was a major process 
coexistent with chronic rejection. 4 grafts were lost and 
reqUired retransplantation. The liver function studies 
were analvzed prior to FK506. Cnlike the previous 
groups. most of the liver function abnormalities were 
noted as elevations of serum transaminases. No patient 
was grosslv jaundiced. The total bilirubin. SGOT and 
SGPT pnor to and six months after FK'506. were: 1.1 mg! 
dLvs. 0.6 mg;dL.173 lUlL vs8'5 lUlL and 291 lUlL vs 110 
lUlL. respectively. 
Histologic response a/the liver a i10graJt. In each case 
where histopathologic changes were predominant. the 
influence of FK506 on the initial findings of rejection or 
hepatitis were evaluated in serial followup biopsies. The 
followup period for liver biopsies did not coincide with 
the followup period for liver function studies. This may 
account for discrepancies between the magnitude of re-
sponses between histologic and biochemical parameters. 
In the subset of 18 patients with acute cellular rejec-
tion. 14 grafts were still functioning. Ten of the 14 patients 
had nonnalization of histologic rejection findings. Four 
had no changes, although in two patients the followup 
biopsy was perfonned within two weeks following FK506 
conversion. This is somewhat different than the biochemi-
cal parameters. in which all patients improved. 
Patients with chronic rejection could be categOrized 
into those patients who failed rescue and required retrans-
plantation and those patients who were successfully res-
cued. Thirteen of the 22 patients with successful rescues 
showed histologic improvement while the remaining 9 
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TABLE 2. 
LIVER FUNCTIONS OF PATIENTS WITH CHRONIC REJECTION 
Liver Function Pre-FK506 Values Six Months Values 
Failed Rescue# FltnCllOntng Grafts Functioning Grafts 
TBIL<mgldU 21.0 -d 1.1 
SGOTCIU/L) 282 204 97 
SGPT(IUlU 412 297 126 
ALKCIUlU 666 -i78 326 
GGTP (lUlU 1661 1316 677 
'Total number of pattenrs = 33; 11 were failed rescue attempts: 22 were functioning grafts at six months. 
showed no changes. The microscopic improvement 
appeared as lessened portal inf1ammation and diminished 
lobular changes or cholestasis. Because of the posslbilitv 
of sampling errors. H is not possible to state that bile 
ductule regrowth was seen. however the percentage of 
duct loss was less in several patients. In the group of 
patients who failed rescue. the pre-FK506 biopSies gener-
ally demonstrated a ., late" stage of chronic rejection. Seven 
of 11 failures were categorized as showing bile duct loss in 
excess of 50 percent of portal triads. In addition. other 
microscopic and macroscopic stigmata. including mild 
portal inflammation. hepatocyte dropout in Zone 3, 
perivenular fibrosis and obliterative arteriopathy could be 
found. 
Hepatitis occurs as an independent pathologic proc-
ess. When coexistent hepatitis and rejection occur. it is 
often difficult to predict which process contnbutes dispro-
portionately. When both processes eXIst. treatment 15 
initiated towards the one which may be controlled. 
Twenty patients with coexistent hepatitis and chronic 
rejection were switched to FK506. Four grafts were lost 
and required retransplantation. Hepatitis was a factor in 
three cases. After FK506 conversion. 10 of the 16 showed 
stable or improved portal inflammation. Worsening of the 
histologic hepatitis was seen in six patients characterized 
by increased lobular disarray, steatosis and hepatocyte ne-
crosis with a paucity of inflammation. 
Discussion 
This report summarizes our experience on the useful-
ness of FK506 conversion for patients with refractory 
rejection while on cvclosporine. The correlation of histo-
logic improvement In patients with biochemical improve-
ment In liver functions confirms that FK506 can arrest and 
reverse acute rejection and even "early" chronic rejection.s 
Several hallmarks of "late" chronic rejection. including 
"vanishing bile duct syndrome". obliterative arteriopathy 
and fibroSIS. are high risks factors for failure. however no 
'ilOgle histopathologic parameter predicted nonresponse 
to therapy. Given the high risks assoClated with retrans-
plantation. we believe that a trial of FK506 conversion 
therapy may be indicated for refractory rejection. if the 
patient's condition allows. 
An intensive workup is indicated in order to assure 
that liver function abnormalities are related to rejection 
and not mechanical or infectious etiologies. We have 
IOstituted a rigid protocol. which includes liver biopsies. 
invasive and non-invasive radiologic examination as well 
as a careful search for viral infections prior to FK506 
conversion. We have found that up to 20 percent of 
patients will have liver dysfunction unrelated to rejection. 
Once all causes other than rejectlon have been ruled out. 
the timing of FK506 conversion is considered. A trial of 
FK506 therapy for 2-4 weeks. followed by reevaluation. 
should be the minimum course. In patients with progres-
sive acute cellular rejection. conversion to FK506 may also 
require other anti-rejection therapy, dependent on clinical 
situations. We have employed augmented steroids or' 
OKT3 if an aggressive acute cellular relection is not stabi-
lized within 24-48 hours after FK506 is started. Liver 
function tests should normalize or greatly improve within 
the first two weeks after conversion. 
In patients with chronic rejection. it is unrealistic to 
expect that stigmata of chronic rejection will reverse 
within a short period of time. In fact. we have had several 
cases of remarkable recoveries. some of which have taken 
2-3 months. In the high risk group of patients with chronic 
rejection. many of whom had received previous azathi-
oprine. OKT3 andlor high doses of steroids. over 60 
percent treated by conversion to FK'506 had both clinical 
and histopathologic responses. This phenomenon. not 
seen before with patients on cyclosporine. OKT3 or 
azathioprine. may be related to a hepatotrophic effect of 
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FKS06 on the liver.'110 The limitation in the ability to rescue 
:1 chronically relecting liver allograft IS likely to be the 
:lrterial inflow and the requirement for some residuum of 
portal biliarv structures. Those patients with a diagnosIs of 
chromc relection who did not respond to FKS06 conver-
sion had histopathologic evidence of end stage chronic 
relection with obliteration of the vascular lumen and 
:ldvanced destruction of intrahepatic bile duct structures. 
FK506 has been shown to reverse ongoing acute 
cellular relection in animal models when started early in 
the rejection episode. 11 This study demonstrates a marked 
ability of FKS06 to reverse ongoing acute and even "early" 
chronic rejection. The quality of dose adjustability in the 
treatment of rejection has always been considered to be 
limited to steroids. We have recently reported that FKS06 
can also reverse rejection in other organ systems. includ-
ing heart. Il.13 kidneyu and even chronic gratt-versus-host 
disease. j.13 
FKS06 and cvclosponne share m:lnv slmtiar biologiC 
properties. Both immunosuppressive agents have speCi-
ficity towards T cells. Both drugs inhibit interleukin-2 
syntheSis and. therefore. T cell proliferation. 14.1~ The 
mechanism whereby these drugs inhibit T cell function is 
thought to be in an inhibition of specific receptors which 
are peptidyl-prolyl cis-trans isomerases. 16.17 While some of 
the neurotoxicity. nephrotoxicity and diabetogenic effects 
of both drugs are similar. there are marked differences. 
The incidence of hypertension is less while gingival hyper-
plasia and hirsutism is Virtually nonexistent with FKS06. 
l. 
3. 
-to 
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